Enveric Biosciences, Inc.

The momentum for this stock is not very good. Enveric Biosciences, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Enveric Biosciences, Inc. .

News

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Enveric Biosciences (NASDAQ: ENVB) (Enveric), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that...\n more…

Enveric Biosciences (NASDAQ:ENVB) Announces Earnings Results

Zolmax Enveric Biosciences (NASDAQ:ENVB - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus...\n more…

Enveric Biosciences (NASDAQ:ENVB) Releases Earnings Results, Beats Estimates By $0.30 EPS

Ticker Report Enveric Biosciences (NASDAQ:ENVB - Get Free Report) posted its earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of...\n more…

Short Interest in Enveric Biosciences, Inc. (NASDAQ:ENVB) Grows By 1,760.3%

Ticker Report Enveric Biosciences, Inc. (NASDAQ:ENVB - Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 2,450,000 shares, a growth of...\n more…

Enveric Biosciences eligible for $61M in radiation dermatitis deal with Aries

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries License for Treatment of Radiation Dermatitis and Other Conditions